Quick Answer
Telomir Pharmaceuticals, Inc. reported Diluted EPS of $0.33 per share (loss) for fiscal year 2025.
Telomir Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.33 | +41.1% |
| 2024 | -$0.56 | -216.7% |
| 2023 | $0.48 | +1700.0% |
| 2022 | -$0.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | +85.0% | -117.6% |
| June 30, 2025 | $0.17 | +240.0% | +342.9% |
| March 31, 2025 | -$0.07 | +69.6% | +65.0% |
| September 30, 2024 | -$0.20 | -233.3% | -500.0% |
| June 30, 2024 | $0.05 | +183.3% | +121.7% |
| March 31, 2024 | -$0.23 | -1050.0% | -283.3% |
| September 30, 2023 | -$0.06 | — | +0.0% |
| June 30, 2023 | -$0.06 | — | -200.0% |
- Telomir Pharmaceuticals, Inc. showed an increase of +41.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Telomir Pharmaceuticals, Inc.’s diluted eps has declined by 1000.0% (from $0.03 per share (loss) to $0.33 per share (loss)).
- The most recent figure is from Telomir Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: